AVROBIO

$14.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+0.21%) Today

$0.00 (0.00%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, and ETFs commission-free!

About AVRO

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA. The listed name for AVRO is AVROBIO, Inc. Common Stock.

CEO

Geoff MacKay

Employees

—

Headquarters

Cambridge, Massachusetts

Founded

2015

Market Cap

511.41M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

508.60K

High Today

$14.23

Low Today

$13.81

Open Price

$14.08

Volume

322.61K

52 Week High

$29.32

52 Week Low

$9.76

Collections

Analyst Ratings

75%

of 8 ratings

Buy

75%

Hold

25%

Sell

AVRO Earnings

-$1.01

-$0.67

-$0.34

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 15, Pre-Market